利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.019 秒)

    SUBSTITUTED FURO[2,3-B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
    4.
    发明授权
    SUBSTITUTED FURO[2,3-B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS 有权
    取代的呋喃并[2,3-B]吡啶衍生物作为大麻素-1受体调节剂

    公开(公告)号：EP2146997B1

    公开(公告)日：2010-11-10

    申请号：EP08742647.4

    申请日：2008-04-07

    申请人： Merck Sharp & Dohme Corp.

    发明人： CLEMENTS, Matthew, J. ,  DEBENHAM, John, S. ,  HALE, Jeffrey, J. ,  MADSEN-DUGGAN, Christina, B. ,  WALSH, Thomas, F. ,  PERESYPKIN, Andrey, V. ,  HELMY, Roy

    IPC分类号： C07D491/048 ,  A61K31/4355 ,  A61P3/04 ,  A61P25/18 ,  A61P25/22 ,  A61P25/28

    CPC分类号： C07D491/048

    摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.

    摘要翻译： 结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，并且可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明化合物可用作治疗精神病，记忆缺陷，认知障碍，阿尔茨海默氏病，偏头痛，神经病，包括多发性硬化症和格林 - 巴利综合征的神经炎症和病毒性脑炎的炎症性后遗症的中枢作用药物 ，脑血管意外，头部外伤，焦虑症，压力，癫痫，帕金森病，运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍，肥胖或饮食失调的治疗，以及治疗哮喘，便秘，慢性肠假性梗阻，肝硬化，非酒精性脂肪肝疾病（NAFLD） ），非酒精性脂肪性肝炎（NASH）和促进觉醒。

    SUBSTITUTED PYRANO [2, 3 - B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
    5.
    发明授权
    SUBSTITUTED PYRANO [2, 3 - B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS 有权
    取代的吡喃并[2，3 - B]吡啶衍生物ALS大麻素-1受体调节剂

    公开(公告)号：EP2109615B1

    公开(公告)日：2011-03-09

    申请号：EP08713287.4

    申请日：2008-01-25

    申请人： Merck Sharp & Dohme Corp.

    发明人： DEBENHAM, John, S. ,  HALE, Jeffrey, J. ,  HUO, Pei ,  MADSEN-DUGGAN, Christina, B. ,  WALSH, Thomas, F. ,  YAN, Lin

    IPC分类号： C07D491/052 ,  C07D491/16 ,  C07D495/16 ,  A61K31/436 ,  A61P1/00 ,  A61P25/00

    CPC分类号： C07D491/052 ,  C07D491/16 ,  C07D495/16

    摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, Huntington's disease movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.